<DOC>
	<DOCNO>NCT01667562</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate progression-free survival safety erlotinib participant locally advance metastatic non-small cell lung cancer activate mutation tyrosine kinase domain epidermal growth factor receptor ( EGFR ) . Participants receive daily oral dos erlotinib disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Erlotinib Participants With Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Diagnosis locally advance metastatic nonsmall cell lung cancer activate mutation tyrosine kinase domain EGFR Measurable disease accord RECIST Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy great equal ( &gt; /= ) 12 week Adequate hematological , liver renal function Participants asymptomatic stable cerebral metastasis receive medical treatment Previous chemotherapy treatment EGFR metastatic disease Treatment investigational agent le 3 week enrollment History neoplasm nonsmall cell lung cancer ( except carcinoma situ uterine cervix , basal cell skin carcinoma , prostate carcinoma ) Participants symptomatic cerebral metastasis Any significant ophthalmologic abnormality Unstable systemic disease Coumarins use Evidence disease , neurological metabolic dysfunction , physical examination laboratory find contraindicate use investigational drug Participants preexist parenchymal lung disease pulmonary fibrosis , lymphangiosis carcinomatosis Participants know infection human immunodeficiency virus ( HIV ) , Hepatitis B ( HBV ) , Hepatitis C ( HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>